Healthcare IoT Security Market Current Scenario with Forecast to 2031

AI in Biopharmaceutical Development Market Assessment worth $ 16.4 Billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI in Biopharmaceutical Development Market- by Type (Monoclonal Antibodies, Vaccines, and Recombinant Proteins), Application (Research and Discovery, Clinical Development, Manufacturing & Supply Chain and Other Subsegments), End-User (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations or Contract Research Organizations (CRO), and Academic & Government Research Institutes), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get Free Sample Copy of Report : https://www.insightaceanalytic.com/request-sample/1227
According to the latest research by InsightAce Analytic, the global AI in the Biopharmaceutical Development market is valued at US$ 452.33 Million in 2021, and it is expected to reach US$ 16.4 Billion by 2030, with a CAGR of 49.3% during a forecast period of 2022-2030.
The frontier technology most likely to have a game-changing influence on the biopharmaceutical industry is artificial intelligence (AI). AI method domains (ML) include reasoning, solution search, knowledge representation, and machine learning. It can help with decision-making, selecting the best course of treatment for a patient, customizing medications, and maintaining clinical data for future drug research. In drug discovery, AI can differentiate between hit and lead compounds, enabling quicker therapeutic target confirmation and structural design optimization.
The market is expanding as artificial intelligence gains popularity in the biopharmaceutical sector. Rising medication research expenses and greater awareness of AI's efficacy will also be significant market growth drivers in the upcoming years. A low trial failure rate, an abundance of software developers for drug discovery, and a high demand for software among big pharma & biotech businesses and research institutes are also contributing to the market's growth. Adopting AI technologies shortens the length of the clinical trial cycle, removes potential roadblocks, and increases efficiency and accuracy. The most significant issues in this industry for AI-based biopharmaceutical development are the higher costs of the equipment, applications, and software. Other market barriers for the projection period include a lack of data sets for medication discovery, a shortage of experienced workers, and a lack of rules and ethical standards for using artificial intelligence in healthcare.
Due to many software and technology vendors, North America is anticipated to mainly contribute to AI in the Biopharmaceutical Development market over the forecast years. Additionally, the growing prevalence of chronic diseases and rising costs for R&D activities in the United States drive the North American biopharmaceuticals market. The United States is the centre of the world's life sciences innovations and actively participates in biopharmaceutical companies' influential global capital investments. In addition, the Asia Pacific AI in Biopharmaceutical Development market is expected to grow significantly during the forecast period. One of the main factors influencing the market is the expansion of international market players into Asian markets such as China, India, and others. Due to this region's low manufacturing and operating costs, Asian nations are also becoming more popular as a hub for biomanufacturing new medicines.
Major market players operating in AI in the biopharmaceutical Development market include IBM Watson Health, Google (Alphabet Inc.), Concreto HealthAI, Nvidia Corporation, PathAI, Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Ai-biopharma S.A.S., and Microsoft Corporation, among others, are some key players operating in the AI in Biopharmaceutical Development Market.
Recent collaborations and agreements in the market:
• In April 2021, Microsoft acquired Nuance for $19.7 billion, emphasizing healthcare AI. Microsoft will pay Nuance $19.7 billion in cash. With Nuance's conversational AI and speech recognition technologies under its wing, Microsoft will step up its effort to provide cloud-based AI solutions to the healthcare sector on a larger scale.
• In April 2021, On AI-driven drug discovery, Nvidia worked with AstraZeneca and the University of Florida. Through this partnership, researchers will be able to more quickly assess billions of compounds for possible therapeutic candidates thanks to a model trained using the AI supercomputer Nvidia DGX SuperPOD.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1227
Market Segments
Global AI in Biopharmaceutical Development Market, by Type, 2022-2030 (Value US$ Mn)
• Monoclonal antibodies
• Vaccines
• Recombinant proteins
Global AI in Biopharmaceutical Development Market, by Application, 2022-2030 (Value US$ Mn)
• Research and discovery
• Clinical development
• Manufacturing & supply chain and other subsegments
Global AI in Biopharmaceutical Development Market, by End-User, 2022-2030 (Value US$ Mn)
• Biopharmaceutical manufacturers
• Contract manufacturing organizations (CMOs) or contract research organizations (CROs)
• Academic & government research institutes
Global AI in Biopharmaceutical Development Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America AI in Biopharmaceutical Development Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe AI in Biopharmaceutical Development Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific AI in Biopharmaceutical Development Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America AI in Biopharmaceutical Development Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa AI in Biopharmaceutical Development Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global AI in Biopharmaceutical Development market
 To receive an industry overview and future trends of the AI in Biopharmaceutical Development market
 To analyze the AI in Biopharmaceutical Development market drivers and challenges
 To get information on the AI in Biopharmaceutical Development market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the AI in Biopharmaceutical Development market industry
For More Information @ https://www.insightaceanalytic.com/customisation/1227

Commercial Office Unit No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar,
Pune, Maharashtra 411028

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.